Houston, TX 的 濾泡性淋巴瘤 臨床試驗
18 項針對 濾泡性淋巴瘤 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Md Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
招募中觀察性研究
- Texas Children's Hospital, Houston
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
招募中1/2 期
- Research Site, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Baylor College of Medicine, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
招募中2 期
- Research Site, Houston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
招募中3 期
- Center for Oncology and Blood Disorders, Houston
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
招募中2 期
- MD Anderson Cancer Center, Houston
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
招募中2 期
- M D Anderson Cancer Center, Houston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- University of Texas MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
招募中1 期
- The University of TX MD Anderson Cancer Center, Houston
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
招募中2 期
- Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
招募中1 期
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Houston
其他城市的 濾泡性淋巴瘤 試驗
- New York City, NY24 項研究
- Milwaukee, WI19 項研究
- Nashville, TN18 項研究
- Boston, MA17 項研究
- Baldwin Park, CA16 項研究
- Seattle, WA15 項研究
- Durham, NC15 項研究
- Salt Lake City, UT13 項研究
- Columbus, OH13 項研究
- Chicago, IL12 項研究
- San Antonio, TX12 項研究
- Philadelphia, PA12 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。